eTheRNA Immunotherapies

Scientific Foundation

The company's work is rooted in the understanding that mRNA can be used to instruct the body's own cells to produce specific proteins or antigens, thereby triggering targeted immune responses. mRNA-based approaches offer several advantages over traditional therapeutic modalities, including the ability to encode virtually any protein, rapid development timelines, flexibility in design, and a manufacturing process that does not require handling live pathogens or complex protein purification.

eTheRNA's foundational research focused on activating and directing the immune system, particularly through the stimulation of T-cell responses, which are critical for fighting cancer and certain chronic infections. This immunological emphasis distinguishes the company's scientific orientation and informs its product pipeline.

Core Technology Platforms

TriMix Technology

The cornerstone of eTheRNA's scientific platform is its proprietary TriMix technology. TriMix is a combination of three mRNA molecules that encode specific immune-stimulating proteins. These molecules work together to activate dendritic cells, which are the key antigen-presenting cells of the immune system responsible for orchestrating adaptive immune responses.

The three components of TriMix are designed to:

• Promote the maturation and activation of dendritic cells
• Enhance the stimulatory capacity of these cells
• Drive the generation of potent, antigen-specific T-cell responses

By co-delivering TriMix with mRNA encoding tumor-associated antigens or other target antigens, eTheRNA aims to generate robust and durable immune responses capable of recognizing and destroying diseased cells. The TriMix approach was designed to potentiate immune activation without the need for ex vivo manipulation of cells in certain applications, supporting a more direct in vivo administration strategy.

Lipid Nanoparticle and Delivery Systems

To enable effective delivery of mRNA into target cells, eTheRNA has worked on formulation and delivery technologies, including lipid-based nanoparticle systems. Effective delivery is one of the central challenges in mRNA therapeutics, as mRNA molecules are fragile and must be protected from degradation while being efficiently taken up by the appropriate cells. The company's delivery research aims to optimize stability, cellular uptake, and the targeting of relevant immune cell populations.

Therapeutic Focus Areas

Oncology

Cancer immunotherapy represents a primary focus for eTheRNA. The company's approach seeks to harness the immune system to recognize and attack tumor cells by presenting tumor-specific or tumor-associated antigens to the immune system in combination with the immune-activating TriMix components. One of the notable areas of clinical interest has been melanoma, a cancer type that has historically been responsive to immunotherapeutic strategies. The company has pursued candidates designed to elicit strong anti-tumor T-cell responses as either standalone treatments or in combination with other immunotherapeutic agents.

Infectious Diseases

eTheRNA has applied its mRNA platform to the development of vaccines targeting infectious diseases. The flexibility of mRNA technology allows the company to design vaccine candidates against a range of pathogens. During the global response to emerging infectious threats, the company contributed to efforts exploring mRNA-based vaccine approaches, leveraging the rapid design and adaptability inherent to the mRNA modality.

Other Applications

Beyond oncology and infectious disease, the underlying versatility of the mRNA and TriMix platforms positions eTheRNA to explore additional therapeutic applications where modulation of the immune response is beneficial.

Products and Services

Pipeline Product Candidates

eTheRNA's primary value proposition lies in its pipeline of mRNA-based immunotherapy and vaccine candidates. These candidates are developed internally using the company's proprietary platforms and are advanced through preclinical and clinical evaluation. The lead programs have included cancer immunotherapy candidates focused on indications such as melanoma, as well as vaccine candidates for infectious diseases.

mRNA Design and Development

The company offers expertise in the design and engineering of mRNA constructs optimized for immunotherapy applications. This includes the rational design of antigen-encoding sequences and the integration of immune-stimulating elements through the TriMix approach.

Manufacturing Capabilities

eTheRNA has invested in GMP-compliant manufacturing capabilities to support the production of mRNA-based products for clinical use. In-house manufacturing allows the company to maintain control over quality, supply, and the production process, which is particularly important for advancing candidates through clinical development. The company has also positioned its manufacturing capacity to potentially support partnered programs and contract development activities within the mRNA field.

Partnerships and Collaboration

A significant component of eTheRNA's business model involves collaboration with academic institutions, biopharmaceutical companies, and other partners. Through these collaborations, eTheRNA applies its mRNA and TriMix platforms to co-development programs, providing access to its technology, expertise, and manufacturing know-how. Such partnerships allow the company to broaden the application of its platforms across a wider range of therapeutic targets while sharing development risk and accelerating progress.

Strategic Position and Significance

eTheRNA operates at the intersection of two powerful trends in modern medicine: the rise of immunotherapy as a transformative approach to treating cancer and chronic disease, and the maturation of mRNA as a clinically validated therapeutic modality. The widespread success of mRNA vaccines has heightened interest in the broader potential of mRNA technologies, and companies with established platforms, intellectual property, and manufacturing capabilities occupy a strategically valuable position.

The company's TriMix technology gives it a differentiated approach within the crowded mRNA landscape, emphasizing not only the delivery of antigen-encoding mRNA but also the active stimulation and direction of immune responses. This immunological sophistication reflects eTheRNA's heritage in academic research focused on dendritic cells and T-cell immunity.

Research and Innovation Culture

As a clinical-stage biotechnology company, eTheRNA places strong emphasis on scientific innovation, drawing on multidisciplinary expertise that spans molecular biology, immunology, formulation chemistry, and clinical development. The company's connection to the Belgian and broader European life sciences ecosystem provides access to scientific talent, research collaborations, and a supportive environment for biotech innovation. Belgium in particular has established itself as a notable hub for biotechnology and pharmaceutical research, and eTheRNA contributes to this ecosystem with its specialized focus on mRNA immunotherapeutics.

Conclusion

eTheRNA Immunotherapies is a Belgium-based biopharmaceutical company dedicated to advancing the science of mRNA-based immunotherapy and vaccination. Through its proprietary TriMix technology and complementary delivery and manufacturing capabilities, the company develops product candidates aimed at treating cancer and infectious diseases by activating and directing the body's immune system. With a pipeline of internally developed candidates, a focus on collaborative partnerships, and in-house manufacturing expertise, eTheRNA represents a specialized player in the global mRNA therapeutics field, contributing meaningfully to the ongoing evolution of immunotherapy and the broader promise of RNA-based medicine.